HUTCHMED DRC (HCM) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $13.73 (-0.65%), Market cap $2.05B, P/E ratio 4.51, 52-week low–high $11.95 ~ $19.21.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and
Financial statements, price targets, institutional (13F) holdings and related news for HUTCHMED DRC are updated in real time on BlackAll Trade.
HUTCHMED DRC trades at $13.73 (-0.65%). Real-time quotes and charts are available on BlackAll Trade.
HUTCHMED DRC has a market cap of about $2.05B. Its P/E ratio is 4.51.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the